Core Insights - Liminatus Pharma, Inc. has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited for a USD 30,000,000 equity financing to support its immunotherapy research and development [1][2][3] Company Overview - Liminatus Pharma is a clinical-stage immuno-oncology company focused on developing next-generation CD47-blockade therapies, including its proprietary antibody IBA101, aimed at improving treatment for solid tumors [3] Investment Details - The equity financing will be executed through an earn-out mechanism, with funds expected to be remitted after the registration statement for the resale of shares is effective [1][2] - CTG plans to subscribe to newly issued shares of Liminatus, contingent upon compliance with Nasdaq listing rules and U.S. securities laws [2] Future Cooperation - Discussions for further strategic cooperation, including potential digital bond financing programs, are expected to commence in mid-November 2025, pending the signing of definitive agreements [3] Capital Trust Group Overview - Capital Trust Group is a New Zealand-based investment management firm involved in large-scale institutional and blockchain-enabled financing across various sectors, including healthcare [4]